MAPT and Alzheimer disease: Our previous research indicated that in the brain of AD human and transgenic mice, the expression of CIP2A increased and overexpression of CIP2A induced tau and APP hyperphosphorylation through inhibiting PP2A, causing cognitive and memory impairment and synaptic dysfunction [5].